MRC1 and neoplasm: MMR P/LP carriers also harbored significantly higher tumor mutation burden (TMB) compared to non-carriers (p=1.2e-04), and, consistent with previous findings in MMR-deficient HGG43, 4/6 tumors were considered hypermutant (>10 mutations/Mb; Figure 5D).